Key result
ApoA-I mimetic peptide infusions increased aortic valve area by 25% and decreased valve thickness by 21% compared to saline in rabbits with experimental aortic stenosis.
Why the study?
Does ApoA-I mimetic peptide infusion improve aortic valve area and thickness in a rabbit model of aortic valve stenosis?
RCT (n=15)
randomly
Does ApoA-I mimetic peptide infusion improve aortic valve area and thickness in a rabbit model of aortic valve stenosis?
ApoA-I mimetic peptide infusions induced regression of experimental aortic valve stenosis in rabbits, highlighting a potential novel therapeutic avenue for HDL-based therapies.
Answers are grounded in this paper and cite their sources.
Should not change aortic stenosis management; leaves open HDL-mimetic therapies for future human trials.
BACKGROUND AND PURPOSE: Aortic valve stenosis (AVS) is the most common valvular heart disease, and standard curative therapy remains open heart surgical valve replacement. The aim of our experimental study was to determine if apolipoprotein A-I (ApoA-I) mimetic peptide infusions could induce regression of AVS. EXPERIMENTAL APPROACH: Fifteen New Zealand White male rabbits received a cholesterol-enriched diet and vitamin D(2) until significant AVS was detected by echocardiography. The enriched diet was then stopped to mimic cholesterol-lowering therapy and animals were allocated randomly to receive saline (control group, n=8) or an ApoA-I mimetic peptide (treated group, n=7), three times per week for 2 weeks. Serial echocardiograms and post mortem valve histology were performed. KEY RESULTS: Aortic valve area increased significantly by 25% in the treated group after 14 days of treatment (P=0.012). Likewise, aortic valve thickness decreased by 21% in the treated group, whereas it was unchanged in controls (P=0.0006). Histological analysis revealed that the extent of lesions at the base of valve leaflets and sinuses of Valsalva was smaller in the treated group compared with controls (P=0.032). The treatment also reduced calcification, as revealed by the loss of the positive relationship observed in the control group (r=0.87, P=0.004) between calcification area and aortic valve thickness. CONCLUSIONS AND IMPLICATIONS: Infusions of ApoA-I mimetic peptide lead to regression of experimental AVS. These positive results justify the further testing of high-density lipoprotein (HDL)-based therapies in patients with valvular aortic stenosis. Regression of aortic stenosis, if achieved safely, could transform the clinical treatment of this disease.
No takes yet. Share an insight, caveat, or question.
Busseuil et al. (2008) conducted an RCT in Aortic valve stenosis (n=15). ApoA-I mimetic peptide vs. saline was evaluated on Aortic valve area (p=0.012). ApoA-I mimetic peptide infusions increased aortic valve area by 25% and decreased valve thickness by 21% compared to saline in rabbits with experimental aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: